A pharmaceutical company introduced a new medicine that effectively treated a common ailment, improving patients' quality of life. However, a small group of patients reported side effects. Who are the primary external stakeholders affected by the new medicine?• a. Patients, experiencing side effects• b. Investors, pleased with increased profits• c. Employees, developing a new medicine• d. Regulatory authorities, monitoring safety and efficacy

Healthcare Group, a pharmaceutical firm, takes a methodical outlook to enterprise risk management. Throughout its value chain, from the early identification of new, promising compounds to the manufacture and distribution of drugs to patients, it is constantly exposed to risks. In the pharmaceutical industry, certain uncertainties are inevitable, such as delays or failures of promising new drugs in the R&D pipeline. Other challenges, such as supply disruptions and competitive threats, are well known to every global manufacturing organisation.R&D risk, supply chain risk, safety and quality risks, commercialisation risk, security risk, financial risk and regulatory risk are some of the most significant threats that it faces.Based on the given information, which framework is Healthcare Group more inclined to use as a base in its risk management process?ISO 31000COSOCOBITNone of the above

PharmaceuticalsInnovation in the pharmaceutical market is a debated and highly charged topic. For instance, it charges high prices due to research and development costs and risk factors. However, it can provide positive external benefits. If a new drug saves a life, it produces a private benefit to the company as well as the saved individual. At the same time, other parties also benefit. For example, family and friends no longer have to fear losing a close friend or loved one, and the grief it would bring.Who is the third party?What is the externalities?Good or bad?When dose the spillover occurs?

What is the primary goal of medical affairs in pharmaceutical commercialization?Select one:a. Ensuring compliance with regulationsb. Conducting clinical trialsc. Building relationships with healthcare professionalsd. Maximizing sales and revenue

You work as the risk manager for a pharmaceutical manufacturer. Your industry is presently undergoing creative change. The chief financial officer has sought your advice on the risk to current operations and activities given the nature of the industry disruption. Your advice would consider:Group of answer choicesThe highly skilled researchers who may seek employment elsewhereThe marketing process which promotes your drugs to doctors.The extensive supply chain which enables the sourcing of high quality, pure chemicals.The intellectual property which may become obsolete if an alternative drug is developed.

Granting a pharmaceutical company a patent for a new medicine will lead toGroup of answer choicesreduced incentives for pharmaceutical companies to invest in research and development.lower quantities of output than without the patent.a product that is priced higher than it would be without the exclusive rights.lower prices than without the patent.